Latest news with #Stifel
Yahoo
2 hours ago
- Business
- Yahoo
Stifel Reports Second Quarter 2025 Results
ST. LOUIS, July 30, 2025 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today reported net revenues of $1.3 billion for the three months ended June 30, 2025, compared with $1.2 billion a year ago. Net income available to common shareholders was $145.7 million, or $1.34 per diluted common share, compared with $156.0 million, or $1.41 per diluted common share for the second quarter of 2024. Non-GAAP net income available to common shareholders was $185.6 million, or $1.71 per diluted common share for the second quarter of 2025. Ronald J. Kruszewski, Chairman and Chief Executive Officer, said 'We achieved the best second quarter in our history, generating over $1.28 billion in net revenue and $1.71 in core EPS despite a challenging April. These results reflect the strength of our diversified, advice-driven model and the consistency of our performance across market cycles. With our strongest financial advisor recruiting quarter in 10 years, growing momentum in our Institutional business, and continued progress in key growth areas, we are confident about the second half of the year and beyond.' Highlights The Company reported net revenues of $1.28 billion, the third best quarter in its history, driven by higher transactional revenues, asset management revenues, net interest income, and capital raising revenues. Non-GAAP net income available to common shareholders of $1.71 per diluted common share. Transactional revenues increased 11% over the year-ago quarter. Asset management revenues increased 6% over the year-ago quarter. Capital raising revenues increased 4% over the year-ago quarter. Record client assets of $516.5 billion, up 9% over the year-ago quarter. Added 82 financial advisors during the quarter, including 20 experienced employee advisors and 1 experienced independent advisor and 36 experienced advisors from B. Riley. Non-GAAP pre-tax margin of 20.3%. Annualized return on tangible common equity (ROTCE) (5) of 21.7%. Tangible book value per common share (7) of $33.30, up 4% from prior year. Media Contact: Neil Shapiro (212) 271-3447 | Investor Contact: Joel Jeffrey (212) 271- 3610 | Financial Summary (Unaudited) (000s) 2Q 2025 2Q 2024 6m 2025 6m 2024 GAAP Financial Highlights: Net revenues $1,284,286 $1,217,932 $2,539,755 $2,380,970 Net income (1) $145,734 $155,973 $189,406 $310,228 Diluted EPS (1) $1.34 $1.41 $1.73 $2.82 Comp. ratio 60.3% 59.3% 59.3% 58.9% Non-comp. ratio 23.1% 22.1% 29.8% 22.4% Pre-tax margin 16.6% 18.6% 10.9% 18.7% Non-GAAP Financial Highlights: Net revenues $1,284,378 $1,217,941 $2,539,833 $2,380,979 Net income (1) (2) $185,626 $176,570 $239,862 $339,916 Diluted EPS (1) (2) $1.71 $1.60 $2.18 $3.09 Comp. ratio (2) 58.0% 58.0% 58.0% 58.0% Non-comp. ratio (2) 21.7% 21.4% 28.7% 21.8% Pre-tax margin (3) 20.3% 20.6% 13.3% 20.2% ROCE (4) 15.2% 15.1% 9.8% 14.7% ROTCE (5) 21.7% 21.9% 13.8% 21.4% Global Wealth Management () Net revenues $845,631 $801,135 $1,696,190 $1,591,635 Pre-tax net income $306,056 $299,173 $432,461 $589,921 Total client assets $516,532 $474,137 Fee-based client assets $206,319 $179,749 Bank loans (6) $21,448 $19,820 Institutional Group Net revenues $419,779 $390,721 $804,708 $742,097 Equity $220,168 $217,694 $456,360 $424,111 Fixed Income $199,611 $173,027 $348,348 $317,986 Pre-tax net income $61,040 $48,813 $88,471 $85,922 Global Wealth Management Global Wealth Management reported net revenues of $845.6 million for the three months ended June 30, 2025 compared with $801.1 million during the second quarter of 2024. Pre-tax net income was $306.1 million compared with $299.2 million in the second quarter of 2024. Highlights Ranked No. 1 in Overall Employee Advisor Satisfaction for the third straight year. Added 82 financial advisors during the quarter, including 20 experienced employee advisors, and 1 experienced independent advisor, and 36 experienced financial advisors from B. Riley, with a combine total trailing 12 month production of $50.6 million. Record client assets of $516.5 billion, up 9% over the year-ago quarter. Fee-based client assets of $206.3 billion, up 15% over the year-ago quarter. Net revenues increased 6% from a year ago: Transactional revenues increased 3% over the year-ago quarter reflecting an increase in client activity. Asset management revenues increased 6% over the year-ago quarter reflecting higher asset values and net new asset growth. Net interest income increased 8% over the year-ago quarter driven by balance sheet growth, partially offset by lower interest rates and changes in the deposit mix. Total Expenses: Compensation expense as a percentage of net revenues increased to 49.7% primarily as a result of higher compensable revenues. Provision for credit losses was primarily impacted by specific reserves on individual credits and overall loan growth in the retained portfolio. Non-compensation operating expenses as a percentage of net revenues increased to 14.1% primarily as a result of an increase in the provision for credit losses, partially offset by revenue growth over the year-ago quarter. Summary Results of Operations (000s) 2Q 2025 2Q 2024 Net revenues $845,631 $801,135 Transactional revenues 182,666 177,308 Asset management 403,574 380,737 Net interest income 254,148 236,281 Investment banking 6,224 5,780 Other income (981) 1,029 Total expenses $539,575 $501,962 Compensation expense 420,240 392,941 Provision for credit losses 8,328 2,954 Non-comp. opex 111,007 106,067 Pre-tax net income $306,056 $299,173 Compensation ratio 49.7% 49.0% Non-compensation ratio 14.1% 13.7% Pre-tax margin 36.2% 37.3% Institutional Group Institutional Group reported net revenues of $419.8 million for the three months ended June 30, 2025 compared with $390.7 million during the second quarter of 2024. Institutional Group reported pre-tax net income of $61.0 million for the three months ended June 30, 2025 compared $48.8 million in the second quarter of 2024. Highlights Investment banking revenues remained consistent with a year ago: Advisory revenues decreased 3% from the year-ago quarter driven by lower levels of completed advisory transactions. Fixed income capital raising revenues increased 12% over the year-ago quarter primarily driven by higher bond issuances. Equity capital raising revenues decreased 4% from the year-ago quarter driven by lower volumes. Fixed income transactional revenues increased 21% from a year ago: Fixed income transactional revenues increased from the year-ago quarter driven by higher client activity in a more volatile market environment and realized trading gains. Equity transactional revenues increased 16% from a year ago: Equity transactional revenues increased from the year-ago quarter primarily driven by increased client activity. Total Expenses: Compensation expense as a percentage of net revenues increased to 61.4% primarily driven by higher variable compensation expense as a result of an improving operating environment. Non-compensation operating expenses as a percentage of net revenues decreased to 24.1% primarily as a result of higher revenues. Summary Results of Operations (000s) 2Q 2025 2Q 2024 Net revenues $419,779 $390,721 Investment banking 227,236 227,501 Advisory 127,305 131,411 Fixed income capital raising 53,744 48,143 Equity capital raising 46,187 47,947 Fixed income transactional 129,117 106,685 Equity transactional 61,489 52,907 Other 1,937 3,628 Total expenses $358,739 $341,908 Compensation expense 257,697 239,036 Non-comp. opex. 101,042 102,872 Pre-tax net income $61,040 $48,813 Compensation ratio 61.4% 61.2% Non-compensation ratio 24.1% 26.3% Pre-tax margin 14.5% 12.5% Other Matters Highlights The Company repurchased $83.0 million of its outstanding common stock during the second quarter. Weighted average diluted shares outstanding decreased primarily as a result of share repurchases, partially offset by the increase in the Company's share price. The Board of Directors declared a $0.46 quarterly dividend per share payable on June 16, 2025 to common shareholders of record on June 2, 2025. The Board of Directors declared a quarterly dividend on the outstanding shares of the Company's preferred stock payable on June 16, 2025 to shareholders of record on June 2, 2025. 2Q 2025 2Q 2024 Common stock repurchases Repurchases (000s) $83,039 $17,597 Number of shares (000s) 970 229 Average price $85.62 $76.97 Period end shares (000s) 102,190 102,518 Weighted average diluted shares outstanding (000s) 108,847 110,285 Effective tax rate 27.5% 27.1% Stifel Financial Corp. (8) Tier 1 common capital ratio 14.5% 14.8% Tier 1 risk based capital ratio 17.5% 17.8% Tier 1 leverage capital ratio 10.8% 11.1% Tier 1 capital (MM) $4,116 $4,044 Risk weighted assets (MM) $23,588 $22,734 Average assets (MM) $38,013 $36,275 Quarter end assets (MM) $39,860 $37,809 Agency Rating Outlook Fitch Ratings BBB+ Stable S&P Global Ratings BBB Stable Conference Call Information . The conference call may include forward-looking statements. All interested parties are invited to listen to Stifel's Chairman and CEO, Ronald J. Kruszewski, by dialing (866) 409-1555 and referencing conference ID 2769458. A live audio webcast of the call, as well as a presentation highlighting the Company's results, will be available through the Company's web site, For those who cannot listen to the live broadcast, a replay of the broadcast will be available through the above-referenced web site beginning approximately one hour following the completion of the call. Company Information Stifel Financial Corp. (NYSE: SF) is a financial services holding company headquartered in St. Louis, Missouri, that conducts its banking, securities, and financial services business through several wholly owned subsidiaries. Stifel's broker-dealer clients are served in the United States through Stifel, Nicolaus & Company, Incorporated, including its Eaton Partners and Miller Buckfire business divisions; Keefe, Bruyette & Woods, Inc.; and Stifel Independent Advisors, LLC. The Company's broker-dealer affiliates provide securities brokerage, investment banking, trading, investment advisory, and related financial services to individual investors, professional money managers, businesses, and municipalities. Stifel Bank and Stifel Bank & Trust offer a full range of consumer and commercial lending solutions. Stifel Trust Company, N.A. and Stifel Trust Company Delaware, N.A. offer trust and related services. To learn more about Stifel, please visit the Company's website at For global disclosures, please visit A financial summary follows. Financial, statistical and business-related information, as well as information regarding business and segment trends, is included in the financial supplement. Both the earnings release and the financial supplement are available online in the Investor Relations section at The information provided herein and in the financial supplement, including information provided on the Company's earnings conference calls, may include certain non-GAAP financial measures. The definition of such measures or reconciliation of such measures to the comparable U.S. GAAP figures are included in this earnings release and the financial supplement, both of which are available online in the Investor Relations section at Cautionary Note Regarding Forward-Looking Statements This earnings release contains certain statements that may be deemed to be 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements in this earnings release not dealing with historical results are forward-looking and are based on various assumptions. The forward-looking statements in this earnings release are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by the statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, among other things, the following possibilities: the ability to successfully integrate acquired companies or the branch offices and financial advisors; a material adverse change in financial condition; the risk of borrower, depositor, and other customer attrition; a change in general business and economic conditions; changes in the interest rate environment, deposit flows, loan demand, real estate values, and competition; changes in accounting principles, policies, or guidelines; changes in legislation and regulation; other economic, competitive, governmental, regulatory, geopolitical, and technological factors affecting the companies' operations, pricing, and services; and other risk factors referred to from time to time in filings made by Stifel Financial Corp. with the Securities and Exchange Commission. For information about the risks and important factors that could affect the Company's future results, financial condition and liquidity, see 'Risk Factors' in Part I, Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2024. Forward-looking statements speak only as to the date they are made. The Company disclaims any intent or obligation to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. Summary Results of Operations (Unaudited) Three Months Ended Six Months Ended (000s, except per share amounts) 6/30/2025 6/30/2024 % Change 3/31/2025 % Change 6/30/2025 6/30/2024 % Change Revenues: Commissions $ 200,669 $ 183,317 9.5 $ 193,670 3.6 $ 394,339 $ 368,793 6.9 Principal transactions 172,603 153,574 12.4 141,660 21.8 314,263 292,588 7.4 Investment banking 233,460 233,281 0.1 237,942 (1.9) 471,402 447,230 5.4 Asset management 403,608 380,757 6.0 409,541 (1.4) 813,149 748,233 8.7 Other income 3,690 16,180 (77.2) 10,581 (65.1) 14,271 21,130 (32.5) Operating revenues 1,014,030 967,109 4.9 993,394 2.1 2,007,424 1,877,974 6.9 Interest revenue 477,056 498,152 (4.2) 475,632 0.3 952,688 1,004,980 (5.2) Total revenues 1,491,086 1,465,261 1.8 1,469,026 1.5 2,960,112 2,882,954 2.7 Interest expense 206,800 247,329 (16.4) 213,557 (3.2) 420,357 501,984 (16.3) Net revenues 1,284,286 1,217,932 5.4 1,255,469 2.3 2,539,755 2,380,970 6.7 Non-interest expenses: Compensation and benefits 774,936 722,719 7.2 732,220 5.8 1,507,156 1,402,414 7.5 Non-compensation operating expenses 295,530 268,319 10.1 459,885 (35.7) 755,415 532,971 41.7 Total non-interest expenses 1,070,466 991,038 8.0 1,192,105 (10.2) 2,262,571 1,935,385 16.9 Income before income taxes 213,820 226,894 (5.8) 63,364 237.4 277,184 445,585 (37.8) Provision for income taxes 58,765 61,600 (4.6) 10,372 466.6 69,137 116,716 (40.8) Net income 155,055 165,294 (6.2) 52,992 192.6 208,047 328,869 (36.7) Preferred dividends 9,321 9,321 0.0 9,320 0.0 18,641 18,641 0.0 Net income available to common shareholders $145,734 $155,973 (6.6) $43,672 233.7 $189,406 $310,228 (38.9) Earnings per common share: Basic $1.41 $1.50 (6.0) $0.42 235.7 $1.82 $2.98 (38.9) Diluted $1.34 $1.41 (5.0) $0.39 243.6 $1.73 $2.82 (38.7) Cash dividends declared per common share $0.46 $0.42 9.5 $0.46 0.0 $0.92 $0.84 9.5 Weighted average number of common shares outstanding: Basic 103,349 104,150 (0.8) 104,764 (1.4) 104,049 104,217 (0.2) Diluted 108,847 110,285 (1.3) 110,635 (1.6) 109,791 110,156 (0.3)Non-GAAP Financial Measures (9) Three Months Ended Six Months Ended (000s, except per share amounts) 6/30/2025 6/30/2024 6/30/2025 6/30/2024 GAAP net income $155,055 $165,294 $208,047 $328,869 Preferred dividend 9,321 9,321 18,641 18,641 Net income available to common shareholders 145,734 155,973 189,406 310,228 Non-GAAP adjustments: Merger-related (10) 20,376 13,821 33,037 25,975 Restructuring and severance (11) 27,041 9,961 27,041 9,961 Provision for income taxes (12) (7,525) (3,185) (9,622) (6,248) Total non-GAAP adjustments 39,892 20,597 50,456 29,688 Non-GAAP net income available to common shareholders $185,626 $176,570 $239,862 $339,916 Weighted average diluted shares outstanding 108,847 110,285 109,791 110,156 GAAP earnings per diluted common share $1.42 $1.50 $1.90 $2.98 Non-GAAP adjustments 0.37 0.19 0.45 0.27 Non-GAAP earnings per diluted common share $1.79 $1.69 $2.35 $3.25 GAAP earnings per diluted common share available to common shareholders $1.34 $1.41 $1.73 $2.82 Non-GAAP adjustments 0.37 0.19 0.45 0.27 Non-GAAP earnings per diluted common share available to common shareholders $1.71 $1.60 $2.18 $3.09GAAP to Non-GAAP Reconciliation (9) Three Months Ended Six Months Ended (000s) 6/30/2025 6/30/2024 6/30/2025 6/30/2024 GAAP compensation and benefits $774,936 $722,719 $1,507,156 $1,402,414 As a percentage of net revenues 60.3% 59.3% 59.3% 58.9% Non-GAAP adjustments: Merger-related (10) (2,946) (5,764) (7,002) (11,297) Restructuring and severance (11) (27,041) (9,961) (27,041) (9,961) Total non-GAAP adjustments (29,987) (15,725) (34,043) (21,258) Non-GAAP compensation and benefits $744,949 $706,994 $1,473,113 $1,381,156 As a percentage of non-GAAP net revenues 58.0% 58.0% 58.0% 58.0% GAAP non-compensation expenses $295,530 $268,319 $755,415 $532,971 As a percentage of net revenues 23.1% 22.1% 29.8% 22.4% Non-GAAP adjustments: Merger-related (10) (17,338) (8,048) (25,957) (14,669) Non-GAAP non-compensation expenses $278,192 $260,271 $729,458 $518,302 As a percentage of non-GAAP net revenues 21.7% 21.4% 28.7% 21.8% Total adjustments $47,417 $23,782 $60,078 $35,936Footnotes (1) Represents available to common shareholders. (2) Reconciliations of the Company's GAAP results to these non-GAAP measures are discussed within and under 'Non-GAAP Financial Measures' and 'GAAP to Non-GAAP Reconciliation.' (3) Non-GAAP pre-tax margin is calculated by adding total non-GAAP adjustments and dividing it by non-GAAP net revenues. See 'Non-GAAP Financial Measures' and 'GAAP to Non-GAAP Reconciliation.' (4) Return on average common equity ('ROCE') is calculated by dividing annualized net income applicable to common shareholders by average common shareholders' equity or, in the case of non-GAAP ROCE, calculated by dividing non-GAAP net income applicable to commons shareholders by average common shareholders' equity. (5) Return on average tangible common equity ('ROTCE') is calculated by dividing annualized net income applicable to common shareholders by average tangible shareholders' equity or, in the case of non-GAAP ROTCE, calculated by dividing non-GAAP net income applicable to common shareholders by average tangible common equity. Tangible common equity, also a non-GAAP financial measure, equals total common shareholders' equity less goodwill and identifiable intangible assets and the deferred taxes on goodwill and intangible assets. Average deferred taxes on goodwill and intangible assets were $84.3 million and $75.8 million as of June 30, 2025 and 2024, respectively. (6) Includes loans held for sale. (7) Tangible book value per common share represents shareholders' equity (excluding preferred stock) divided by period end common shares outstanding. Tangible common shareholders' equity equals total common shareholders' equity less goodwill and identifiable intangible assets and the deferred taxes on goodwill and intangible assets. (8) Capital ratios are estimates at the time of the Company's earnings release, July 30, 2025. (9) The Company prepares its Consolidated Financial Statements using accounting principles generally accepted in the United States (U.S. GAAP). The Company may disclose certain 'non-GAAP financial measures' in the course of its earnings releases, earnings conference calls, financial presentations and otherwise. The Securities and Exchange Commission defines a 'non-GAAP financial measure' as a numerical measure of historical or future financial performance, financial position, or cash flows that is subject to adjustments that effectively exclude, or include, amounts from the most directly comparable measure calculated and presented in accordance with U.S. GAAP. Non-GAAP financial measures disclosed by the Company are provided as additional information to analysts, investors and other stakeholders in order to provide them with greater transparency about, or an alternative method for assessing the Company's financial condition or operating results. These measures are not in accordance with, or a substitute for U.S. GAAP, and may be different from or inconsistent with non-GAAP financial measures used by other companies. Whenever the Company refers to a non-GAAP financial measure, it will also define it or present the most directly comparable financial measure calculated and presented in accordance with U.S. GAAP, along with a reconciliation of the differences between the non-GAAP financial measure it references and such comparable U.S. GAAP financial measure. (10) Primarily related to charges attributable to integration-related activities, signing bonuses, amortization of restricted stock awards, debentures, and promissory notes issued as retention, additional earn-out expense, and amortization of intangible assets acquired. These costs were directly related to acquisitions of certain businesses and are not representative of the costs of running the Company's on-going business. (11) The Company recorded severance costs associated with workforce reductions in certain of its foreign subsidiaries. (12) Primarily represents the Company's effective tax rate for the period applied to the non-GAAP in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Business
- Yahoo
Celestica (CLS) Jumps to New High on Strong Income, Optimistic Outlook
We recently published . Celestica Inc. (NYSE:CLS) is one of the best-performing stocks on Monday. Celestica rallied for a third day on Tuesday to hit a new high as investors took heart from an impressive earnings performance, higher growth guidance, and bullish analyst ratings. During the session, the company soared to as high as $208.66 before paring gains to end the day just up by 16.51 percent at $202 apiece. In its earnings release, Celestica Inc. (NYSE:CLS) said net income in the second quarter of the year more than doubled to $211 million from $95 million in the same period last year, while revenues increased by 21 percent to $2.89 billion from $2.39 billion year-on-year. In the first half, net income increased by 59 percent to $297.2 million from $186.8 million, while revenues rose by 20 percent to $5.5 billion from $4.6 billion. Given the strong performance, Celestica Inc. (NYSE:CLS) raised its 2025 growth outlook, with revenues now pegged at $11.55 billion versus the $10.85 billion previous guidance. Adjusted EPS was also expected to settle at $5.5, versus the $5 previously. Following the results, investment firm Stifel raised its price target for Celestica Inc. (NYSE:CLS) to $230 from $150 previously, while maintaining a 'buy' recommendation. While we acknowledge the potential of CLS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Business
- Yahoo
Alamos Gold Inc. (AGI) Experiences Strong Stock Momentum Amid Rising Cost Pressures in 2025
Alamos Gold Inc. (NYSE:AGI) is included in our list of the . A closeup image of a miner holding a pile of gold nuggets, a representation of the company's royalty. For Alamos Gold Inc. (NYSE:AGI), this year is marked by strong stock momentum, evolving analyst expectations, and rising cost pressures. While AGI's shares are up 43.17% YTD, investor sentiment remains mixed after a challenging Q1. For the quarter, the company reported total cash costs of $1,193 per ounce, up from $910 a year earlier. At the same time, all-in sustaining costs increased to $1,805 from $1,265. Yet, the company's stable revenue and profitability offered some reassurance to investors. Following Q1 results, cautious optimism is noted among the analysts. On July 21, 2025, Stifel increased its price target from $33.61 to $35.08, maintaining a 'Buy' rating. Still, the analyst reduced its EPS estimates from $0.42 to $0.40. For FY2025 and FY2026, the analyst projected earnings at $1.63 and $2.07 per share, respectively. Meanwhile, on July 16, National Bank lowered its price target on Alamos Gold Inc. (NYSE:AGI) from $38.18 to $37.27, maintaining an 'Outperform' rating. With a presence in Canada, Mexico, and the United States, Alamos Gold Inc. (NYSE:AGI) is focused on producing gold. It is included in our list of the best gold stocks. While we acknowledge the potential of AGI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Most Undervalued Cloud Stocks Under $10 According to Hedge Funds and 11 Best Mineral Stocks to Buy According to Hedge Funds. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Business
- Yahoo
Stifel Keeps Buy Rating on Alto Neuroscience (ANRO)
Alto Neuroscience, Inc. (NYSE:ANRO) is one of the 11 Best New Penny Stocks to Buy Right Now. On June 26, Stifel reiterated its 'Buy' rating on Alto Neuroscience, Inc. (NYSE:ANRO) with a price target of $10. This decision came after the company announced Phase 2 proof-of-concept results for its drug ALTO-203 in major depressive disorder (MDD) patients with elevated levels of anhedonia. A close-up of a healthcare professional in a lab coat, handling a pipette with medications for neuroscience diseases. The trial showed mixed results. However, Stifel analysts noted that ALTO-203 showed significant positive effects in improving sustained attention and increased wakefulness. The strongest results were seen in patients with more abnormal theta/beta EEG ratios at baseline, which is a biomarker that can be used to help diagnose ADHD. Stifel described the trial as exploratory with low expectations, noting that although this program keeps some options open for Alto Neuroscience, Inc. (NYSE:ANRO), it does not change the core investment view as the company prioritizes its late-stage pipeline. The next steps for ALTO-203 are yet to be determined. Alto Neuroscience, Inc. (NYSE:ANRO) is a clinical-stage biopharmaceutical company focused on the development of treatment options for neuropsychiatric disorders. While we acknowledge the potential of ANRO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
a day ago
- Business
- Yahoo
Stifel Maintains Buy Rating on Lexeo Therapeutics (LXEO)
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is one of the 11 Best New Penny Stocks to Buy Right Now. On July 7, Stifel reiterated its 'Buy' rating for Lexeo Therapeutics, Inc. (NASDAQ:LXEO) with a price target of $21. This decision came after the company announced that the FDA gave Breakthrough Therapy Designation to its treatment called LX2006. A scientist in a laboratory examining a test tube filled with a medication used to treat hypertension and cardiovascular diseases. The FDA granted Breakthrough Therapy Designation for LX2006 in both cardiac and neurologic measures of Friedreich ataxia (FA). Lexeo Therapeutics, Inc. (NASDAQ:LXEO) also shared that LX2006 has been selected to participate in the FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program, which is designed to expedite clinical development timelines. Stifel sees the Breakthrough Therapy Designation as a good sign for Lexeo Therapeutics, Inc.'s (NASDAQ:LXEO) regulatory prospects. The firm noted that this designation suggests that the FDA may be more flexible for rare disease gene therapies. Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is a clinical-stage genetic medicine company focused on developing therapies for cardiovascular diseases. While we acknowledge the potential of LXEO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
